Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Seer, Inc.NASDAQ: SEER

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $2.61M (cash outflow) rose 73.6% year over year, ahead of the -10.2% change in trailing-twelve-month financing cash flow.

Context

  • Financing cash flow amounted to 65.6% of revenue in FY2025, down 16.9 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +73.6% holds above the trailing-twelve-month pace of -10.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.61M-1923.8% QoQ
Last fiscal yearDec 2025
-$10.57M-8.1% YoY
LTMMar 2026
-$11.67M-10.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.6%——
1 year-8.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(10.57M) USD
Year-over-year change
+8.1%

Financing Cash Flow vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.2% is the 13th highest of 18, against a peer median of +231.0%.
  • Financing cash flow amounts to 77.6% of revenue for SEER, versus a peer median of 741.0%.
SEER Competitors
Financing Cash Flow for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$777.92M USD+55.7%+86.4%741.0%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$659.43M USD+231.0%+66.5%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$358.67M USD+263.5%+14.0%835.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$306.39M USD+17210.3%+114.1%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$261.21M USD+28.6%+26.8%37.2%
SANASana Biotechnology, Inc.LTM Mar 2026$127.62M USD+790.4%+197.0%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.91M USD+1085.3%+379.4%364.0%
PHVSPharvaris N.V.LTM Sep 2026€112.22M EUR-30.3%+164.8%—
PEPGPepGen Inc.LTM Mar 2026$109.5M USD+6044.6%-1.3%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7755.9%+68.0%329441.9%
STTKShattuck Labs, Inc.LTM Mar 2026$70.43M USD+7606.1%+538.8%7043.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.66M USD-51.5%-16.6%179.5%
QSIQuantum-Si incorporatedLTM Mar 2026$47.05M USD-44.2%+268.4%2540.4%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.38M USD+42373.9%-88.3%—
SEERSeer, Inc.LTM Mar 2026$11.67M USD-10.2%—77.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$1.47M USD-99.4%——
MOLNMolecular Partners AGLTM Mar 2026CHF 1.3M CHF-109.0%-9.9%—
MNOVMediciNova, Inc.LTM Mar 2026$244.02K USD—+213.5%40.9%
NKTXNkarta, Inc.LTM Mar 2026$147K USD+180.8%-91.4%—
Peer median (excluding SEER) —+231.0%+68.0%741.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.